Prognostic value of beta1-integrin (=CD29) in serous adenocarcinomas of the ovary.
BACKGROUND
Integrins are heterodimeric transmembranous proteins, comprised of two transmembrane subunits, called alpha and beta. They bind to various structures of the extra cellular matrix (ECM) and are responsible for cell-cell interactions. The aim of the current study was to evaluate the prognostic value of beta1-integrin in patients suffering from malignant serous surface epithelial-stromal tumors of the ovary.


METHODS
With immunohistochemical methods we investigated 76 formalin-fixed, paraffin-embedded tissue samples. FIGO stages I, II, III and IV were present in 18, 10, 41 and 7 cases, respectively.


RESULTS
12 sections (15.8%) stained positive for beta1-integrin (=CD29), 64 sections (84.2%) showed no expression of beta1-integrin. The product limit method by Kaplan and Meier showed no statistical significance of beta1-integrin expression on overall survival, (p = 0.1005, log-rank test). Also the univariate Cox regression analysis showed no statistical significance of beta1-integrin expression on overall survival (p=0.1066), whereas in the multivariate analysis, adjusted for grading, FIGO stage and residual tumor, the expression of beta1-integrin turned out to be significantly correlated with reduced overall survival (p=0.0208).


CONCLUSIONS
Our results using multivariate Cox regression analysis indicated a shorter overall survival for patients with positive staining for beta1-integrin in malignant serous surface epithelial-stromal tumors of the ovary. This pilot study warrants further investigation of the role of beta1-integrin in ovarian cancer.
Müller-Klingspor
V
V
Department of Gynecology and Obstetrics, Vienna University Medical School, Austria.
Hefler
L
L
Obermair
A
A
Kaider
A
A
Breitenecker
G
G
Leodolte
S
S
Kohlberger
P
P
D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D018284:Cystadenocarcinoma, Serous / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019012:Integrin beta1 / Q000096:biosynthesis*; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D012044:Regression Analysis; D017154:Stromal Cells / Q000473:pathology
D014408:Biomarkers, Tumor; D019012:Integrin beta1